Search research articles
Contact Us
Filters
Showing results (331-340 of 346) with videos related to
Page
of 35
Sort By:
Transplantation and Cellular Therapy
|
June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS
Uday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML
Courtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
The Lancet. Haematology
|
June 27, 2020
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
Elias Jabbour, Guillaume Richard-Carpentier, Yuya Sasaki, et al.
American Journal of Hematology
|
December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality
Abhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Blood Advances
|
April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia
Abhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Blood Advances
|
July 11, 2025
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Sanam Loghavi, Ziyi Li, et al.
Cancer
|
November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia
Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.
Haematologica
|
June 6, 2020
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
Abhishek Maiti, Caitlin R Rausch, Jorge E Cortes, et al.
Leukemia
|
March 6, 2026
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms
Kelly S Chien, Ziyi Li, Luca Lanino, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 346) with videos related to
Sort By:
Page
of 35
Transplantation and Cellular Therapy
|
June 12, 2026
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS
Uday R Popat, Konstantinos Lontos, Roland Bassett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML
Courtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)
Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
The Lancet. Haematology
|
June 27, 2020
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
Elias Jabbour, Guillaume Richard-Carpentier, Yuya Sasaki, et al.
American Journal of Hematology
|
December 2, 2020
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality
Abhishek Maiti, Wei Qiao, Koji Sasaki, et al.
Blood Advances
|
April 1, 2021
Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia
Abhishek Maiti, Courtney D DiNardo, Sa A Wang, et al.
Blood Advances
|
July 11, 2025
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Sanam Loghavi, Ziyi Li, et al.
Cancer
|
November 25, 2024
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia
Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, et al.
Haematologica
|
June 6, 2020
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
Abhishek Maiti, Caitlin R Rausch, Jorge E Cortes, et al.
Leukemia
|
March 6, 2026
Performance of molecular scoring systems in hypomethylating agent-treated myelodysplastic neoplasms
Kelly S Chien, Ziyi Li, Luca Lanino, et al.
Page
of 35